Charles River Laboratories International, Inc. is expanding its cell therapy contract development and manufacturing (CDMO) facility in Memphis, TN. The expanded space is suitable for clinical and commercial cell therapy manufacturing, with an additional nine state-of-the-art processing suites, adding to an existing 16 cleanrooms.
The suites use advanced cleanroom facility technology and are designed to be fully compliant with current good manufacturing practice (GMP) and international regulatory standards. They can accommodate flexible configurations to support client requirements, and are designed for high volume production, along with options for dual production lines for late stage clinical- and commercial manufacture.
“This expansion builds on the Memphis site’s demonstrable expertise and commitment to supporting cell and gene therapy clients, from early target identification through clinical and commercial-scale manufacturing,” says Birgit Girshick, Charles River corporate executive VP & COO. “We look forward to continuing close partnerships with our clients and supporting projects to bring these potentially curative therapies to patients.”
Read more about the expansion here.